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INTRODUCTION: 
Considerable hard work has been done on the 
development of new drug delivery system named 
Controlled Drug Delivery System. It has prolonged 
action formulations giving continuous release of their 
active ingredients at a predetermined rate and 
predetermined time. The vital objective for the 
development of controlled release dosage forms is to 
prolong the duration of action, increase safety margin of 
high potency drugs due to better control of plasma levels, 
reduce fluctuations in plasma concentration, reduce 
serious side effects and to provide assurance for higher 
patient compliance1. 
Approaches are being adopted to achieve these goals by 
paying considerable attention either towards controlling 
the distribution of drug by incorporating it in a carrier 
system, or altering the structure of the drug at the 
molecular level, or controlling the input of the drug into 
the bioenvironment to ensure an appropriate profile of 
distribution. 
In past few decades vesicles have become the vehicles of 
choice in drug delivery. Lipid vesicles are found to be of 
value in immunology, membrane biology, diagonistic 
techniques, and most recently, genetic engineering. 
Vesicles can play a major role in modeling biological 
membranes and in the transport and targeting of active 
agents. Encapsulation of drug in vesicular structures can 
be predicted to prolong the existence of drug in 
systematic circulation and perhaps, reduce the toxicity if 
selective uptake can be achieved. The phagocytic uptake 
of systemic delivery of the drug loaded vesicular 
delivery system provides efficient methods for delivery 
of drug directly to the site of infection, leading to the 
reduction of drug toxicity with no adverse effects. 
Vesicular drug delivery reduces the cost of therapy by 
improving bioavailability of medication, especially in 
case of poorly soluble drugs. They can incorporate both 
hydrophilic and lipophilic drugs. These systems delay 
drug elimination of rapidly metabolisable drugs, 
functions as sustained release systems and solve the 
problems of drug’s insolubility, instability and rapid 
degradation. Consequently a number of vesicular 
delivery systems such as liposomes, transferosomes, 
pharmacosomes, neosomes or preniosomes, emulsomes 
etc, have been developed. 
Many synthetic amphiphiles form vesicles, but as most 
are ionic and relatively toxic, they are generally 
unsuitable for use as drug carrier vesicles. Formation by 
some members of dialkyl poly-oxyethylene ether non-
ionic surfactant series was reported by Okahata et al58 
and Handjani-Vila et al59. They reported formation of 
vesicular system on hydration of mixture of cholesterol 
and a single alkyl-chain non ionic surfactant. The 
resultant vesicles, which have been termed ‘niosomes’ 
,can entrap solutes, are osmotically active, stable60 and 
require non-special conditions such as low temperature 
or inert atmosphere for production or storage.  
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ABSTRACT: 
In the recent years nanotechnology has brought revolutionary changes in the field of life sciences which includes novel drug 
delivery systems, diagnostics, nutraceuticals and biomedicals for implants and prosthesis. Sustained and Controlled release 
drug products are often formulated to permit the establishment and maintenance of drug concentration at site of action for 
longer interval of time such as liposomes, niosomes, ethosomes, transferosomes, etc. ‘Proniosomal technique’ is the one 
among them. Proniosomes are dry products derived from niosomes. They are water soluble carrier particles that are coated 
with surfactant and can be hydrated to form niosomal dispersion immediately before use on brief agitation in hot aqueous 
media. They are being used in order to minimize the problems associated with niosome’s physical stability such as 
aggregation, fusion, leaking and to provide additional convenience in transportation, distribution, storage and dosing etc. In all 
comparisons, proniosomes are more promising than conventional niosomes. 
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Since then a number of non-ionic surfactants have been 
used to prepare vesicles viz. polyglycerol alkyl 
ethers59,60,61, glycosyl dialkyl ethers62, crown ethers63, 
ester linked surfactants64, poly-oxyethylene alkyl 
ether59,65,66 and a series of spans and tweens67,68,69,70.   
NIOSOMES: 
Niosomes are multilamellar or unilamellar vesicles 
obtained on hydration of synthetic non-ionic surfactant, 
with or without incorporation of cholesterol or other 
lipids2. These particles can act as drug reservoir3 and 
have gained wide attention by researchers for their use as 
drug targeting agents since early 1980s.  
The non ionic surfactants for this use are usually single 
alkyl chain surfactant or sorbitan esters. They are 
biodegradable, biocompatible and non immunogenic in 
nature. The size of niosomes is microscopic and lies in 
nanometric scale. 
These vesicles are analogous to the liposomes 
(phospholipid vesicles). Niosomes represent one of the 
promising drug delivery systems, with particular interest 
in delivery applications including nasal, pulmonary, 
transdermal and ophthalmic delivery. Niosomal vesicles 
can encapsulate both lipophilic and hydrophilic drugs 
and protect them against acidic and enzymatic effects in 
vivo44. They behave in vivo like liposomes as they are 
able to prolong the circulation of encapsulated drug 
altering its organ distribution and metabolic stability71 
and release them at a slow rate to sustain the drug effect. 
Moreover, they can solubilise poorly soluble compounds, 
providing a tangible strategy to resolve formulation 
problems of many therapeutic molecules. 
 
Figure 1:  Structure of a Niosome 
PREPARATION OF NIOSOMES FROM 
PRONIOSOMES BY HYDRATION: 
The niosomes can be prepared from the proniosomes (as 
shown in figure 2) by adding the aqueous phase with the 
drug to the proniosomes with brief agitation at a 
temperature greater than the mean transition phase 
temperature of the surfactant i.e, 
T > Tm 
Where, 
T = Temperature 
Tm = Mean phase transition temperature
 
 
                                    Figure 2: Formation of niosomes from proniosomes 
MERITS OF NIOSOMES OVER OTHER 
VESICLES: 
 They are osmotically stable. Drug molecules with a 
wide range of solubility can be accommodated in 
niosomes; they are able to entrap hydrophilic drug 
by partitioning these molecules into their 
hydrophobic domain. 
 They can reduce drug toxicity because of their 
nonionic nature. 
 Need low cost of production as no special conditions 
are required for handling and storage of niosomes. 
 Non-ionic surfactants are biodegradable, 
biocompatible and non-immunogenic. Due to the 
presence of ester bond, phospholipids are easily 
hydrolyzed51. 
 They can be tailored according to the desired 
situation by modifying their structural characteristics 
(composition, fluidity and size). 
 They can enhance performance of drug by 
improving bioavailability and controlled delivery at 
a particular site. 
 Niosomal dispersion in an aqueous phase can be 
emulsified in a non-aqueous phase to regulate the 
delivery rate of drug and administer normal vesicle 
in external non-ionic phase. 
 The vesicle suspension is water-based vehicle. This 
offers high patient compliance in comparison with 
oily dosage forms. 
 The vesicles may act as a depot, releasing the drug 
in a controlled manner. 
 They improve oral bioavailability of poorly 
absorbed drugs and enhance skin penetration of 
drugs. 
 They can be made to reach the site of action by oral, 
parenteral as well as topical routes. 
 They improve the therapeutic performance of the 
drug molecules by delayed clearance from the 
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circulation, protecting the drug from biological 
environment and restricting effects to target cells. 
 
However, they too are associated with some problems. 
All methods traditionally used for preparation of 
niosomes are time consuming and many involve 
specialized equipments. Most of these methods allow 
only for a predetermined lot size so material is often 
wasted if smaller quantities are required for particular 
dose application4. 
DISADVANTAGES OF NIOSOMES: 
 Physical instability 
 Aggregation 
 Fusion 
 Leaking of entrapped drug 
 Hydrolysis of encapsulated drugs which limits the 
shelf life of the dispersion. 
 To overcome these disadvantages, Proniosomes are 
being taken into consideration. 
PRONIOSOMES: 
Proniosomes are dry formulation of water-soluble carrier 
particles liquid crystalline- compact niosomes 
hybrid72,39,73 that are coated with surfactant and can be 
measured out as needed and hydrated to form niosomal 
dispersion immediately before use on brief agitation in 
hot aqueous media within minutes. The resulting 
niosomes are very similar to conventional niosomes and 
more uniform in size5. 
ADVANTAGES OF PRONIOSOMES OVER 
NIOSOMES:
6,7 
 They avoid problem of physical stability like 
aggregation, fusion, leaking. 
 Avoid hydration of encapsulated drugs limiting the 
shelf-life of the dispersion. 
 Being a dry product they provide additional 
convenience of transportation, distribution and 
storage. 
 Furthermore, unacceptable solvents are avoided in 
proniosomal formulations. These systems are 
directly formulated into transdermal patches and 
don’t require the dispersion of vesicles into 
polymeric matrix. 
 The storage makes proniosomes a versatile delivery 
system with potential for use, with a wide range of 
active compounds. 
TYPES OF PRONIOSOMES:  
1. Dry granular proniosomes 
2. Liquid crystalline proniosomes 
 
1. Dry Granular Proniosomes:  
Dry granular proniosomes involves the coating of water-
soluble carrier such as sorbitol and maltodextrin with 
surfactant. The result of coating process is a dry 
formulation in which each water-soluble particle is 
covered with thin film of surfactant. It is essential to 
prepare vesicles at a temperature above the transition 
temperature of the non-ionic surfactant being used in the 
formulation. These are further categorized as follows: 
(a) Sorbitol based Proniosomes: 
Sorbitol based proniosomes is a dry formulation that 
involves sorbitol as the carrier, which is further coated 
with non-ionic surfactant and is used as niosomes within 
minutes by addition of hot water followed by agitation. 
These are normally made by spraying surfactant mixture 
prepared in organic solvent onto the sorbitol powder and 
then evaporating the solvent. Since the sorbitol carrier is 
soluble in organic solvent, the process is required to be 
repeated till the desired surfactant coating has been 
achieved. The surfactant coating on the carrier is very 
thin and hydration of this coating allows multilamellar 
vesicles to form as the carrier dissolves5,10,11,12. 
(b) Maltodextrin based proniosomes: 
A proniosome formulation based on maltodextrin was 
recently developed that has potential application in 
deliver of hydrophobic or amphiphilic drugs. The better 
of these formulations used to hollow particle with 
exceptionally high surface area. The principal advantage 
with this formulation was the amount of carrier required 
to support the surfactant could be easily adjusted and 
proniosomes with very high mass ratios of surfactant to 
carrier could be prepared13,14. 
2. Liquid Crystalline Proniosomes: 
When the surfactant molecules are kept in contact with 
water, there are three ways through which lipophilic 
chains of surfactants can be transformed into a 
disordered, liquid state called lytorophic liquid 
crystalline state (neat phase). These three ways are- 
 Increasing temperature at kraft point (Tc) 
 Addition of solvent, which dissolves lipids 
 Using both temperature and solvent. 
Neat phase or lamellar phase contains bilayer arranged in 
sheets over one another within intervening aqueous 
layer. These types of structures give typical X-ray 
diffraction and thread like bi-refringent structures under 
polarized microscope. 
FACTORS AFFECTING PHYSICAL NATURE OF 
PRONIOSOMES: 
There are some factors which can affect significantly the 
physical nature of proniosomes5 such as hydration 
temperature, choice of surfactant, nature of membrane, 
nature of drug, etc., (as shown in figure 3). 
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Figure 3: Factors affecting physical nature of proniosomes 
PREPARATION OF PRONEOSOMES: 
Materials to be used: 
Different carriers, non-ionic surfactants and membrane 
stabilizers are used for the proniosome preparation16. 
Commonly used components for proniosomes’ 
formulation are:  
Surfactants: Increase drug flux across the skin56, the 
chemical structure of surfactant influences drug 
entrapment efficiency. Increments in the alkyl chain 
length leads to higher entrapment efficiency8. It also has 
been reported that spans having highest phase transition 
temperature provides highest entrapment for the drug and 
vice versa. e.g., Tween (20, 40, 60, 80), Span (20, 40, 
60). 
Selection of surfactant should be done on the basis of 
HLB value. As Hydrophilic Lipophilic Balance (HLB) is 
a good indicator of the vesicle forming ability of any 
surfactant, HLB number in between 4 and 8 has been 
found to be compatible with vesicle formation. It is also 
reported that the hydrophilic surfactant owing to high 
aqueous solubility on hydration do not reach a state of 
concentrated systems in order to allow free hydrated 
units to exist aggregates and coalesced to form lamellar 
structure. The water soluble detergent polysorbate 20 
also forms niosomes in the presence of cholesterol. This 
is despite the fact that the HLB number of this compound 
is 16.7 Degree of entrapment is affected by the HLB of a 
surfactant. Transition temperature of surfactants also 
affects the entrapment of drug in vesicles. Spans with 
highest phase transition temperature provide the highest 
entrapment for the drug and vice versa8,9.  
Span 40 and Span 60 produces vesicles of larger size 
with higher entrapment of drug. The drug leaching from 
the vesicles is reduced due to high phase transition 
temperature and low permeability. High HLB value of 
Span 40 and 60 results reduction in surface free energy 
which allows forming vesicles of larger size hence large 
area exposed to the dissolution medium and skin. No 
significant difference is observed in the skin permeation 
profile of formulation containing Span 60 and Span 40 
due to their higher phase transition temperature that is 
responsible for their lower permeability.  
The encapsulation efficiency of Tween is relatively low 
as compared to Span. The drug entrapment efficiency 
determined by exhaustive dialysis method was lower 
than that determined by freeze thawing/ centrifugation 
for both span 40 and span 60. In freezing, the drug and 
vesicles are concentrated; particles are closely packed 
with each other resulting in fusion of niosomal vesicles 
due to which larger aggregates are formed having high 
entrapment efficiency74. The geometry of vesicle to be 
formed from surfactants is affected by its structure, 
which is related to critical packing parameters. On the 
basis of critical packing parameters of surfactants can 
predicate geometry of vesicle to be formed. 
Critical packing parameters can be defined using 
following equation, CPP 0.5 micelles form- 
CPP = V/ lc × ao 
CPP= 0.5 – 1 spherical vesicles form 
CPP = 1 inverted vesicles form 
V – Hydrophobic group volume 
lc = the critical hydrophobic group length,, 
a0= the area of hydrophilic head group. 
Span 60 is the good surfactant because it has CPP value 
between 0.5 and 1 
Stabilizers: 
Cholesterol -Prevent leakage of drug formulation. 
Lecithin -Penetration enhancer e.g., Soya and Egg 
lecithin57 
Lecithin: Phosphotidylcholine is the major component 
of lecithin. The name basically depends upon their 
source of origin such as soya lecithin from soya beans 
and egg lecithin from egg yolk. Phosphotidylcholine has 
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low solubility in water16. Incorporation of lecithin in 
proniosomes may act as permeation enhancer, prevents 
the leakage of drug and enhanced the percent drug 
entrapment due to high phase transition temperature. 
However, the incorporation of lecithin into formulation 
requires special treatment during preparation and storage, 
which makes the product less stable and highly 
expensive. So, it may be suggested to prepare 
proniosomes devoid of lecithin component74. The 
vesicles composed of soya lecithin are of larger size then 
vesicle composed of egg lecithin due to difference in the 
intrinsic components. On the basis of penetration 
capability the soya lecithin is considered as a good 
candidate as it contains unsaturated fatty acids, oleic and 
linoleic acid while egg lecithin contains fatty acids17. 
Cholesterol: Cholesterol is an essential component of 
vesicles. Incorporation of cholesterol influence vesicles 
stability and permeability18. Concentration of cholesterol 
plays an important role in entrapment of drug in vesicles. 
The incorporation of cholesterol delay drug release in 
vitro75. The entrapment efficiency and permeation 
increases with increasing cholesterol content and by the 
usage of span 60 which has higher transition 
temperature19. On further increase in cholesterol beyond 
certain concentration level starts disrupting the regular 
bi-layered structure leading to loss of drug entrapment 
and permeation20. Above the phase transition 
temperature cholesterol makes the membrane more 
ordered and abolish the gel to liquid phase transition of 
noisomal system, thus preventing drug leakage from 
proniosomes8,76. Solvent selection of solvent is another 
important aspect as it has great effect on vesicle size and 
drug permeation rate21. Vesicles formed from different 
alcohols are of different sizes and they follow the order: 
ethanol > propanol > butanol > isopropanol. Higher size 
of vesicles in case of ethanol is due to its greater 
solubility in water and smallest size of isopropanolol, 
may be due to branched chain present in it22. Ethanol 
may cause the reduction of lipid polar head interactions 
within the membrane, thereby increased the skin 
permeation23, 24. 
Aqueous phase: Enhances drug entrapment efficiency of 
vesicles e.g., Hot water, Buffer, Glycerol. 
Phosphate buffer 7.4, 0.1% glycerol and hot water are 
mainly used aqueous phase for proniosomes. pH of the 
hydrating medium also play important role in entrapment 
efficiency. The aqueous medium might influence the 
tactness of proniosomes, thus affecting their entrapment 
efficiency25,26. 
Sugar: Provides flexibility in surfactant and other 
component ratio alters the drug distribution e.g., 
Maltodextrin, Sorbitol Carrier which is selected for 
proniosomes’ preparation should have characteristics like 
free flow ability, non-toxicity, poor solubility in the 
loaded mixture solution and good water solubility for 
ease of hydration. 
Maltodextrin: is a polysaccharide. It has minimal 
solubility in organic solvent. Thus it is possible to coat 
maltodextrin particles by simply adding surfactant in 
organic solvent. The use of maltodextrin as carrier in 
Proniosomes preparation permitted flexibility in the ratio 
of surfactant and other components which can be 
incorporated. Coating sorbitol results in solid cake like 
mass.  
Solvent: Enhance skin permeation e.g., Ethanol, 
Methanol, Propanolol, Isopranolol. 
METHODS OF PREPARING PRONIOSOMES: 
1. Slurry method: 
Proniosomes can be prepared from a stock solution of 
surfactants and cholesterol in suitable solvent. The 
required volume of surfactant and cholesterol stock 
solution per gram of carrier and drug should be dissolved 
in the solvent in round bottom flask containing the 
carrier (maltodextrin or lecithin). Additional chloroform 
can be added to form the slurry in case of lower 
surfactant loading. The flask has to be attached to a 
rotary flash evaporator to evaporate solvent at 50-60 rpm 
at a temperature of 45±20 C and a reduced pressure of 
600mm of Hg until the mass in the flask had become a 
dry, free flowing product. Finally, the formulation should 
be stored in tightly closed container under refrigeration 
in light
7,14
. 
2. Spray coated method: 
A 100 ml round bottom flask containing desired amount 
of carrier can be attached to rotary flash evaporator. A 
mixture of surfactant and cholesterol should be prepared 
and introduced into round bottom flask on rotary 
evaporator by sequential spraying of aliquots onto 
carrier’s surface. The evaporator has to be evacuated and 
rotating flask can be rotated in water bath under vacuum 
at 65-70 0C for 15-20 min. This process has to be 
prepared until all of the surfactant solution had been 
applied. The evaporation should be continued until the 
powder becomes completely dry5,28, 29. 
3. Coacervation phase separation method: 
Accurately weighed or required amount of surfactant, 
carrier (lecithin), cholesterol and drug can be taken in a 
clean and dry wide mouthed glass vial (5ml) and solvent 
should be added to it. All these ingredients have to be 
heated and after heating all the ingredients should be 
mixed with glass rod. To prevent the loss of solvent, the 
open end of the glass vial can be covered with a lid. It 
has to be warmed over water bath at 60-70 
0
C for 5 
minutes until the surfactant dissolved completely. The 
mixture should be allowed to cool down at room 
temperature till the dispersion gets converted to a 
Pronisomal gel30. 
METHODS FOR CHARACTERIZATION OF 
PRONIOSOMES: 
1. Vesicle morphology: 
Vesicle morphology involves the measurement of size 
and shape of proniosomal vesicles. Size of proniosomal 
vesicles can be measured by dynamic light scattering 
method in two conditions: without agitation and with 
agitation. Hydration without agitation results in largest 
vesicle size. 
2. Shape and surface morphology: 
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Surface morphology means roundness, smoothness and 
formation of aggregation. It is studied by scanning 
electron microscopy, optical microscopy, transmission 
electron microscopy31. 
3. Scanning electron microscopy: 
The proniosomes are sprinkled onto the double-sided 
tape that is to be affixed on aluminum stubs. The 
aluminum stub is placed in the vacuum chamber of a 
scanning electron microscope. The samples are observed 
for morphological characterization using a gaseous 
secondary electron detector (working pressure: 0.8 tor, 
acceleration voltage: 30.00 KV) XL 30, (Philips, 
Netherlands)7,14. 
4. Optical microscopy: 
The niosomes are mounted on glass slides and viewed 
under a microscope with magnification of 1200X for 
morphological observation after suitable dilution. The 
photomicrograph of the preparation also obtained from 
the microscope by using a digital SLR camera32. 
5. Transmission electron microscopy: 
The morphology of hydrated niosome dispersion is 
determined using transmission electron microscopy. A 
drop of niosome dispersion is diluted 10-fold using 
deionized water. A drop of diluted niosome dispersion is 
applied to a carbon coated 300 mesh copper grid and is 
left for 1 min to allow some of the niosomes to adhere to 
the carbon substrate. The remaining dispersion is 
removed by adsorbing the drop with the corner of a piece 
of filter paper. After twice rinsing the grid (deionized 
water for 3-5 s) a drop of 2% aqueous solution of uranyl 
acetate is applied for 1 s. The remaining solution is 
removed by absorbing the liquid with the tip of a piece of 
filter paper and the sample is air dried. The sample is 
observed at 80 kv. 
6. Angle of repose: 
The angle of repose of dry proniosomes powder is 
measured by a funnel method. The proniosomes powder 
is poured into a funnel which is fixed at a position so that 
the 13mm outlet orifice of the funnel is 5cm above a 
level black surface. The powder flows down from the 
funnel to form a cone on the surface and the angle of 
repose was then calculated by measuring the height of 
the cone and the diameter of its base5,12,14,27, 33. 
7. Rate of hydration: Neubaur’s chamber.  
8. Drug content: 
Drug can be quantified by a modified HPLC method. 
9. Penetration and permeation studies: 
Depth of penetration in proniosomes can be visualized 
by confocal laser scanning microscopy (CLSM). 
10. Encapsulation efficiency: 
The encapsulation efficiency of proniosomes is 
determined after separation of the unentrapped drug. 
A. Separation of unentrapped drug is done by 
the following techniques: 
(a) Dialysis: 
The aqueous niosomal dispersion is dialyzed tubing 
against suitable dissolution medium at room temperature 
then samples are withdrawn from the medium at suitable 
time interval centrifuged and analyzed for drug content 
using UV spectroscopy32. 
(b) Gel filtration: 
The free drug is removed by gel filtration of niosomal 
dispersion through a sephadex G50 column and 
separated with suitable mobile phase and analyzed with 
analytical techniques 34. 
(c) Centrifugation: 
The niosomal suspension is centrifuged and the 
surfactant is separated. The pellet is washed and then 
resuspended to obtain a niosomal suspension free from 
unentrapped drug15. 
B. Determination of entrapment efficiency of 
proniosomes: 
The vesicles obtained after removal of unentraped drug 
by dialysis is then resuspended in 30% v/v of PEG 200 
and 1 ml of 0.1% v/v triton x-100 solution was added to 
solubilize vesicles the resulted clear solution is then 
filtered and analyzed for drug content. The percentage of 
drug entrapped is calculated by using the following 
formula35: 
Percent Entrapment = Amount of drug entrapped/total × 
100 
11. Drug Release Kinetics and Data Analysis: 
In order to understand the kinetics and mechanism of 
drug release, the result of in-vitro drug release study of 
noisome are fitted with various kinetic equations like, 
(a) Zero order, as cumulative % release vs. time, 
C = K0t 
Where, 
k0 = zero order constant expressed in units of 
concentration/time 
t = time in hours. 
(b) Higuchi’s model, as cumulative % drug release vs. 
square root of time. 
Q = KHt1/2 
Where, 
KH = higuchi’s square root of time kinetic drug release 
constant. 
(c) Peppa’s model, as log cumulative % drug release 
vs. log time and the exponent ‘n’ was calculated 
through the slope of the straight line. 
Mt / M0 = btn 
Where, 
Mt = amount of drug release at time t 
M0 = overall amount of the drug 
b = constant 
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n = release exponent indicative of the drug release 
mechanism 
If the exponent n= 0.5 or near, then the drug release 
mechanism is Fickian diffusion, and if n have near 1.0 
then it is Non-Fickian diffusion34. 
12. In-Vitro Methods for Assessment of Drug Release 
from Proniosomes 
(a) Dialysis tubing: 
This apparatus has prewashed dialysis tubing, which can 
be hermetically sealed. The dialysis sac is then dialyzed 
against a suitable dissolution medium at room 
temperature; the samples are withdrawn from the 
medium at suitable intervals, centrifuged and analyzed 
for drug content using suitable method (UV 
spectroscopy, HPLC etc.). The maintenance of sink 
condition is essential36. 
(b) Reverse dialysis: 
In this technique a number of small dialysis tubes 
containing 1 ml of dissolution medium are placed. The 
proniosomes are then displaced into the dissolution 
medium. The direct dilution of the proniosomes is 
possible with this method; however the rapid release 
cannot be quantified using this method36. 
(c) Franz diffusion cell: 
The in-vitro studies can be performed by using Franz 
diffusion cell. Proniosomes are placed in the donor 
chamber of a Franz diffusion cell fitted with a cellophane 
membrane. The proniosomes is then dialyzed against 
suitable dissolution medium at room temperature; the 
samples are withdrawn from the  medium at suitable 
intervals, and analyzed for drug content using suitable 
method (UV spectroscopy, HPLC etc.). The maintenance 
of sink condition is essential37. 
(d) Zeta potential analysis: 
Zeta potential analysis is done for determining the 
colloidal properties of the prepared formulations. The 
suitably diluted proniosomes derived niosome dispersion 
is determined using zeta potential analyzer based on 
Electrophorectic light scattering and laser Doppler 
Velocimetery method. The temperature is set at 25°C. 
Charge on vesicles and their mean zeta potential values 
with standard deviation of 5 measurements are obtained 
directly from the measurement38. 
13. Stability Studies: 
Stability studies are carried out by storing the prepared 
proniosomes at various temperature conditions like 
refrigeration (2°-8°C), room temperature (25°± 0.5°C) 
and elevated temperature (45°C ± 0.5°C) from a period 
of one month to three months. Drug content and 
variation in the average vesicle diameter are periodically 
monitored. ICH guidelines suggests stability studies for 
dry proniosomes powder meant for reconstitution should 
be studied for accelerated stability at 75% relative 
humidity as per international climatic zones and climatic 
conditions27, 39, 40. 
APPLICATIONS OF PRONEOSOMES: 
1. Drug targeting:53 
One of the most useful aspects of proniosomes is their 
ability to target drugs. Proniosomes can be used to target 
drugs to the reticulo-endothelial system. The reticulo-
endothelium system52 (RES) preferentially takes up 
proniosomes vesicles. The uptake of proniosomes is 
controlled by circulating serum factors called opsonins. 
These opsonins mark the niosomes for clearance. Such 
localization of drugs is utilized to treat tumors in animals 
known to metastasize the liver and spleen51. This 
localization of the drugs can also be used for treating 
parasitic infections of the liver. Proniosomes can also be 
utilized for targeting drugs to organs other than the RES. 
A carrier system (such as antibodies) can be attached to 
proniosomes (as immunoglobin bind readily to the lipid 
surface of the noisome) to target them to specific 
organs53. Many cells also possess carbohydrates 
determinates, and this can be exploited by niosomes to 
direct carrier system to particular cells. 
2. Anti-neoplatic treatment:41,42 
Most antineoplastic drugs cause severe side effects. 
Proniosomes can alter the metabolism; prolong 
circulation and half life of the drug, thus decreasing the 
side effects of the drugs. 
3. Treatment of leishmaniasis:43 
Leishmanasis is a disease in which a parasite of the 
genus Leishmania invades the cells of the liver and 
spleen. Commonly prescribed drugs for the treatment are 
derivatives of antimony (antimonials), which in higher 
concentrations can cause cardiac, liver and kidney 
damage. 
4. Delivery of peptide drugs:44 
Oral peptide drug delivery has long been faced with a 
challenge of bypassing the enzymes which would 
breakdown the peptide. Use of proniosomes to 
successfully protect the peptides from gastrointestinal 
peptide breakdown is being investigated. In an in-vitro 
study, oral delivery of a Vasopressin derivative 
entrapped in proniosomes showed that entrapment of the 
drug significantly increased the stability of the peptide. 
5. Uses in studying immune response:45 
Proniosomes are used in studying immune response due 
to their immunological selectivity, low toxicity and 
greater stability. Proniosomes are being used to study the 
nature of the immune response provoked by antigens. 
6. Niosomes as carriers for haemoglobin:46 
Proniosomes can be used as carriers for haemoglobin 
within the blood. The proniosomal vesicle is permeable 
to oxygen and hence can act as a carrier for haemoglobin 
in anaemic patients. 
7. Transdermal drug delivery systems:47 
One of the most useful aspects of proniosomes is that 
they greatly enhance the uptake of drugs through the 
skin. Transdermal drug delivery utilizing proniosomal 
technology is widely used in cosmetics; In fact, it was 
one of the first uses of the niosomes54. Topical use of 
proniosome entrapped antibiotics to treat acne is done. 
The penetration of the drugs through the skin is greatly 
increased as compared to un-entrapped drug55. Recently, 
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transdermal vaccines utilizing proniosomal technology is 
also being researched. The proniosome (along with 
liposomes and transferomes) can be utilized for topical 
immunization using tetanus toxoid. However, the current 
technology in proniosomes allows only a weak immune 
response, and thus more research to be done in this field. 
8. Sustained release:48 
Sustained release action of proniosomes can be applied 
to drugs with low therapeutic index and low water 
solubility since those could be maintained in the 
circulation via proniosomal encapsulation. 
9. Localized drug action:27,49 
Drug delivery through proniosomes is one of the 
approaches to achieve localized drug action, since their 
size and low penetrability through epithelium and 
connective tissue keeps the drug localized at the site of 
administration. Localized drug action results in 
enhancement of efficacy of potency of the drug and at 
the same time reduces its systemic toxic effects e.g. 
Antimonials encapsulated within proniosomes are taken 
up by mononuclear cells resulting in localization of drug, 
increase in potency and hence decrease both in dose and 
toxicity. The evolution of proniosomal drug delivery 
technology is still at an infancy stage, but this type of 
drug delivery system has promise in cancer 
chemotherapy and anti-leishmanial therapy. 
10. Cosmetics or Cosmeceuticals:15 
Proniosome gel can be used as-an effective delivery 
systems for cosmetics and Cosmeceuticals due to their 
unique properties50. For applying therapeutic and 
cosmetic agents onto or through skin requires a non 
toxic, dermatologically acceptable carrier, which not 
only control the release of the agent for prolong action 
but also enhances the penetration to the skin layer. 
Proniosomes gel formulation shows advantages in 
controlled drug delivery improved bioavailability, 
reduced side effects and entrapment of both hydrophilic 
and hydrophobic drugs15. 
CONCLUSION: 
Proniosomes are promising drug carriers for the future 
with greater physical and chemical stability and 
potentially scalable for commercial viability. The 
delivery system holds promise for the effective drug 
delivery for amphiphilic drugs. Various types of drug 
deliveries can be possible using proniosomes based 
niosomes like targeting, ophthalmic, topical, parenteral, 
oral vaccine etc. More researches are carried out in this 
field to know the exact potential in this novel drug 
delivery system. Proniosomes has attracted a great deal 
of attention for the delivery of drugs through transdermal 
route because of the advantages like non-toxicity and 
penetration enhancing effect of surfactants and effective 
modification of drug release properties. Proniosomes in 
dry powder form makes the possibility of convenient unit 
dosing as the proniosome powder can further be 
processed to make beads, tablets or capsules. The 
findings of the studies on proniosomes till date, opens 
the door for the future use of different carrier materials 
with biocompatibility and suitability for the preparation 
of proniosomes. However, future experiments should 
explore the suitability of proniosomes with more drugs 
having defined drawbacks for improved and effective 
intended therapy. Studies should be explored to assess 
the ability of different carrier materials to formulate 
proniosomes and the ability of proniosomes to deliver 
the drugs meant for administration through various 
routes.
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